Quick Answer
Zymeworks Inc. reported Total Revenue of $105.97 million for fiscal year 2025.
Zymeworks Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $105.97M +38.9% |
$76.30M +0.4% |
$76.01M -81.6% |
$412.48M +1446.0% |
$26.68M -31.5% |
$38.95M |
| Revenue (ASC 606) | $105.97M +38.9% |
$76.30M +0.4% |
$76.01M -81.6% |
$412.48M +1446.0% |
$26.68M -31.5% |
$38.95M |
| Net Income | -$81.13M +33.9% |
-$122.69M -3.4% |
-$118.67M -195.4% |
$124.34M +158.7% |
-$211.84M -17.3% |
-$180.55M |
| Diluted EPS | -$1.08 +33.3% |
-$1.62 +5.8% |
-$1.72 -190.5% |
$1.90 +141.2% |
-$4.61 -28.8% |
-$3.58 |
| Total Assets | $346.53M -25.2% |
$463.09M -20.3% |
$580.88M -10.5% |
$648.73M +66.7% |
$389.13M | — |
| Cash and Equivalents | $41.16M -37.7% |
$66.10M -58.0% |
$157.56M -60.7% |
$400.91M +98.6% |
$201.87M | — |
| Stockholders Equity | $268.50M -20.7% |
$338.77M -27.1% |
$464.81M -5.7% |
$492.96M +97.9% |
$249.09M -39.2% |
$409.92M +66.9% |
| R&D Expense | — | — | $143.62M -31.1% |
$208.60M +4.4% |
$199.75M +16.7% |
$171.20M |
| Operating Income | -$92.55M +32.5% |
-$137.11M +0.7% |
-$138.05M -205.8% |
$130.53M +160.5% |
-$215.63M -15.0% |
-$187.47M |
| Shares Outstanding | 74.64M +8.2% |
68.96M -1.6% |
70.12M +11.2% |
63.06M +35.2% |
46.63M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $27.61M | +72.6% | -43.3% |
| Revenue (ASC 606) | September 30, 2025 | $27.61M | +72.6% | -43.3% |
| Net Income | September 30, 2025 | -$19.60M | +34.3% | -946.0% |
| Diluted EPS | September 30, 2025 | -$0.26 | +33.3% | -966.7% |
| Total Assets | September 30, 2025 | $397.27M | -18.5% | -2.7% |
| Cash and Equivalents | September 30, 2025 | $64.83M | -47.0% | -34.0% |
| Stockholders Equity | September 30, 2025 | $320.06M | -12.8% | -4.3% |
| R&D Expense | March 31, 2024 | $32.04M | -30.2% | -2.2% |
| Operating Income | September 30, 2025 | -$22.11M | +35.4% | -3180.4% |
| Shares Outstanding | September 30, 2025 | 75.14M | +8.0% | +0.4% |
- Zymeworks Inc. reported Total Revenue of $105.97 million for fiscal year 2025.
- Zymeworks Inc. showed an increase of +38.9% in Total Revenue compared to the prior fiscal year.
- Zymeworks Inc. reported Revenue (ASC 606) of $105.97 million for fiscal year 2025.
- Zymeworks Inc. showed an increase of +38.9% in Revenue (ASC 606) compared to the prior fiscal year.
- Zymeworks Inc. reported Net Income of -$81.13 million for fiscal year 2025.
- Zymeworks Inc. showed an increase of +33.9% in Net Income compared to the prior fiscal year.
- Zymeworks Inc. reported Diluted EPS of $1.08 per share (loss) for fiscal year 2025.
- Zymeworks Inc. showed an increase of +33.3% in Diluted EPS compared to the prior fiscal year.
- Zymeworks Inc. reported Total Assets of $346.53 million for fiscal year 2025.
- Zymeworks Inc. showed a decrease of -25.2% in Total Assets compared to the prior fiscal year.
- Zymeworks Inc. reported Cash and Equivalents of $41.16 million for fiscal year 2025.
- Zymeworks Inc. showed a decrease of -37.7% in Cash and Equivalents compared to the prior fiscal year.
- Zymeworks Inc. reported Stockholders Equity of $268.50 million for fiscal year 2025.
- Zymeworks Inc. showed a decrease of -20.7% in Stockholders Equity compared to the prior fiscal year.
- Zymeworks Inc. reported R&D Expense of $143.62 million for fiscal year 2023.
- Zymeworks Inc. showed a decrease of -31.1% in R&D Expense compared to the prior fiscal year.
- Zymeworks Inc. reported Operating Income of -$92.55 million for fiscal year 2025.
- Zymeworks Inc. showed an increase of +32.5% in Operating Income compared to the prior fiscal year.
- Zymeworks Inc. reported Shares Outstanding of 74.64 million shares for fiscal year 2025.
- Zymeworks Inc. showed an increase of +8.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: